Here is a collection of tweets from top players in the IVD market, and #GMedTechIVD.
Happy Friday from our team at Revvity! Explore our vast research discovery & development portfolio for pharma, biotech, and CROs. You'll find your trusted favorites are here - with more on the way. http://ms.spr.ly/6015gjCW3
You’ve heard of smartwatches and fitness trackers. Now get ready for the next evolution – biowearables. See how our latest tech could transform how you understand and engage with your health. #WIREDHealth https://abbo.tt/423GmpS
Computational chemistry tools played a leading role at the Spring #ACS Meeting in Indianapolis, highlighting the growing role of data collection, management, and analysis in expediting drug discovery. #computationalchemistry #SignalsResearch
Showcasing the #Revvity faces behind our success - our team of diverse talents makes us who we are. Each individual brings unique skills and perspectives, creating a dynamic force that drives us to revolutionize human health. #WeAreRevvity
Cutting heart failure hospitalizations by nearly half. That’s the power of our CardioMEMS HF System.
Late-breaking data from the MONITOR-HF trial show the big impact of our tiny heart tech: https://abbo.tt/3MTaAHT
What impact did the COVID-19 pandemic have on healthy life expectancy?
The annual BD EMEA healthcare resilience barometer seeks to discern the impact factors such as pandemics have on healthcare resilience.
Learn more here 👉🏻 https://bddy.me/3WL7cCl
Together, we can build a better future for all. And we can’t wait to see the impact of our Pin-point™ gene editing platform on the development of new cell therapy treatments for cancer and other immune-mediated diseases. Explore more @FierceBiotech
AstraZeneca looks to Revvity's gene editing tech to bolster cell therapy work
To rev up its cell therapy engine, AstraZeneca is looking to the aptly named Revvity. | To rev up its cell t...
During his keynote address at Device Talks Boston, BD Chairman, CEO and President @TomPolen_BD reflected on his career at BD and how he is leading the future of the company. Listen to the podcast to hear Tom’s keynote speech.
Straight from DeviceTalks Boston: BD CEO Tom Polen on the pandemic, M&A and successful succession...
Dr. Lee P. Shulman and Dr. Jeff Andrews presented to a full room at #ACOG2023 about why identifying HPV types beyond 16 and 18 (incl. HPV 31) matters, HPV type-specific persistence, and real-world evidence using the BD Onclarity™ HPV assay. Learn more: https://bddy.me/3IDk2fP